Financial Data and Key Metrics Changes - Adjusted EBITDA increased by 18.1% year-over-year to reach $19.9 million, reflecting strong operating leverage despite investments in new markets [49][55] - Practice collections rose by 7.4% year-over-year to $707.7 million, driven by same-store and new provider additions [95] - The company expects a reduction of approximately $198 million in top line revenue for 2024 due to lower risk exposure from Medicare Advantage capitation agreements [56] Business Line Data and Key Metrics Changes - The number of implemented providers increased by 17.3% year-over-year to 4,359, with expectations to reach 4,700 by year-end [95] - Commercial attributed lives grew by 8% year-over-year to 685,000, indicating a strong performance in the commercial book [52] - The company is managing approximately $9 billion of medical spend across various programs, including commercial, MSSP, Medicare Advantage, and Medicaid [53] Market Data and Key Metrics Changes - The company serves approximately 1.14 million attributed lives across more than 100 value-based care contracts, marking a 10% increase from the previous year [69] - The sales pipeline remains strong across all markets, with a robust business development pipeline for new market opportunities [67] Company Strategy and Development Direction - The company aims to build one of the largest primary care-centric delivery networks in the U.S., focusing on risk arrangements to drive future earnings growth [70] - The strategy includes thoughtfully moving lives into increased risk arrangements over time, leveraging clinical operations and performance management [70] - The company plans to maintain a conservative balance sheet while being opportunistic in growth, with over $400 million in cash and no debt [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business momentum and operating execution, closely monitoring medical cost trends and claims data [50] - The company is prepared for potential disruptions in the healthcare market, positioning itself as a stable partner for physician practices [91] - Management reiterated full-year 2024 guidance, expecting continued growth in adjusted EBITDA driven by operating leverage in mature markets [55][56] Other Important Information - The company has a strong balance sheet with cash of $351 million and no debt, positioning it well for future investments [97] - Adjusted EBITDA growth is expected to be driven by operating leverage in mature markets, offsetting new market entry costs [73] Q&A Session Summary Question: Can you unpack the growth in attributed lives? - The growth in attributed lives was influenced by the acquisition of a large IPA in Connecticut and the exit from Delaware, with most growth being organic [6][8] Question: How do you view the fee-for-service side growth? - The company expects seasonality to remain consistent with previous years, with solid performance in the first half positioning it well for the latter half [11][12] Question: Can you provide insights on the capitated MA book and fee-for-service book? - Utilization trends were as expected, with strong physician recruitment and a good pipeline for new markets [15][16] Question: What are the dynamics around shared savings revenue? - The company restructured contracts to preserve EBITDA and earnings power, with a focus on managing care management fees [19][20] Question: How does the company view the current healthcare M&A landscape? - The company sees potential opportunities as private equity and venture capital investments in physician practices may unwind, positioning itself as a stable partner [90][91]

Use of Non-GAAP Financial Information Solid First Quarter Performance and Operating Execution 1 st Quarter 2024 Results May 9, 2024 Parth Mehrotra – Chief Executive Officer David Mountcastle – Chief Financial Officer ● 1Q'24 Performance Building One of the Largest 1 Forward-Looking Statements In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, the Comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) _________________________ Delaware 81-3599420 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 950 N. Glebe Rd., Suite 700 Arlington, Virginia 2220 ...

ARLINGTON, VA – May 9, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2024. | | | | For the Three Months Ended March 31, | | | | --- | --- | --- | --- | --- | --- | | ($ in millions, except per share amounts) | 2024 | | | 2023 | Change (%) | | Total revenue | $ | 415.2 | $ | 386.3 | 7.5 % | | Gross profit | $ | 93.4 | $ | 83.0 | 12.5 % | | Operating income | $ | 0.8 | $ | 6.7 | (87.7)% | | a Net income | $ | 3.0 | $ | 7.3 | (59.3)% | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _______________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, Inc. (Exact ...

Privia Health Group, Inc. (NASDAQ:PRVA) Q4 2023 Earnings Conference Call February 27, 2024 8:00 AM ET Company Participants Robert Borchert - SVP, Investor & Corporate Communications Parth Mehrotra - President and CEO David Mountcastle - CFO Conference Call Participants Joshua Raskin - Nephron Research Unidentified Analyst - Jefferies Lisa Gill - J.P. Morgan Jack Senft - William Blair Sameer Patel - Evercore ISI David Larsen - BTIG Jessica Tassan - Piper Sandler Gary Taylor - TD Cowen Richard Close - Canacco ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | 4 th Quarter 2023 Results February 27, 2024 Parth Mehrotra – David Mountcastle – | Chief Executive Officer Chief Financial Officer | | | | 1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, belie ...

Exhibit 99.1 Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results ARLINGTON, VA – February 27, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2023. The Company achieved each of its full- year guidance metrics for 2023, as highlighted below. Full-Year Performance | | | | For the Years Ended December 31, | | | | --- | --- | --- | --- | --- | --- | | ($ in millions, except per share amo ...

Privia Health Group, Inc (NASDAQ:PRVA) Q3 2023 Earnings Call Transcript November 3, 2023 9:00 AM ET Company Participants Robert Borchert - SVP, Investor & Corporate Communications Parth Mehrotra - President and CEO David Mountcastle - CFO Conference Call Participants Joshua Raskin - Nephron Research Elizabeth Anderson - Evercore ISI Jailendra Singh - Truist Securities Richard Close - Canaccord Genuity Brian Tanquilut - Jefferies Adam Ron - Bank of America Jack Senft - William Blair Benjamin Mayo - Leerink P ...

3 rd Quarter 2023 Results November 3, 2023 Parth Mehrotra – Chief Executive Officer David Mountcastle – Chief Financial Officer 1 Disclaimer Forward-Looking Statements Use of Non-GAAP Financial Information In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basi ...